Results 211 to 220 of about 36,269 (231)

Convergent MAPK pathway alterations mediate acquired resistance to FGFR inhibitors in FGFR2 fusion-positive cholangiocarcinoma.

Journal of Hepatology, 2023
BACKGROUND & AIMS There is a knowledge gap in understanding mechanisms of resistance to FGFR inhibitors (FGFRi) and a need for novel therapeutic strategies to overcome it.
T. DiPeri, Ming Zhao, K. Evans, K. Varadarajan, Tyler J. Moss, Stephen S Scott, Michael P. Kahle, Charnel C. Byrnes, Huiqin Chen, Sunyoung S. Lee, A. Halim, H. Hirai, V. Wacheck, Lawrence N. Kwong, J. Rodón, M. Javle, F. Meric-Bernstam   +16 more
semanticscholar   +1 more source

Updated results of the FOENIX-CCA2 trial: Efficacy and safety of futibatinib in intrahepatic cholangiocarcinoma (iCCA) harboring FGFR2 fusions/rearrangements.

Journal of Clinical Oncology, 2022
4009 Background: Survival outcomes are historically poor in patients (pts) with advanced/metastatic iCCA, with median overall survival (mOS) times of approximately 1 year with first-line gemcitabine plus cisplatin and approximately 6 months with second ...
L. Goyal, F. Meric-Bernstam, A. Hollebecque, C. Morizane, J. Valle, T. Karasic, T. Abrams, R. Kelley, P. Cassier, J. Furuse, H. Klümpen, H. Chang, Li‐Tzong Chen, Y. Komatsu, K. Masuda, D. Ahn, Kate Li, K. Benhadji, V. Wacheck, J. Bridgewater   +19 more
semanticscholar   +1 more source

Final results from a phase II study of infigratinib (BGJ398), an FGFR-selective tyrosine kinase inhibitor, in patients with previously treated advanced cholangiocarcinoma harboring an FGFR2 gene fusion or rearrangement.

, 2021
265Background: Treatment options for cholangiocarcinoma (CCA) after progression on first-line gemcitabine-based therapy are limited.
M. Javle, S. Roychowdhury, R. Kelley, S. Sadeghi, T. Macarulla, D. Waldschmidt, L. Goyal, I. Borbath, A. El-Khoueiry, Weipeng Yong, P. Philip, M. Bitzer, S. Tanasanvimon, Ai Li, A. Pande, S. Shepherd, S. Moran, G. Abou-Alfa   +17 more
semanticscholar   +1 more source

FGFR2 fusion proteins drive oncogenic transformation of mouse liver organoids towards cholangiocarcinoma.

Journal of Hepatology, 2021
BACKGROUND AND AIMS About 15% of intrahepatic cholangiocarcinoma (iCCA) express fibroblast growth factor receptor 2 (FGFR2) fusion proteins (FFs), most often in concert with mutational inactivation of TP53, CDKN2A or BAP1.
Giulia Cristinziano, M. Porru, Dante Lamberti, S. Buglioni, F. Rollo, C. Amoreo, I. Manni, D. Giannarelli, C. Cristofoletti, G. Russo, M. Borad, G. Grazi, M. Diodoro, S. Giordano, A. Sacconi, M. Forcato, S. Anastasi, C. Leonetti, O. Segatto   +18 more
semanticscholar   +1 more source

Prognostic impact of FGFR2/3 alterations in patients with biliary tract cancers receiving systemic chemotherapy: the BITCOIN study.

European Journal of Cancer, 2022
AIM FGFR2 rearrangements have been identified as a novel therapeutic target of biliary tract cancer (BTC). However, reliable prevalence estimates of this molecular alteration and its prognostic role have not been fully elucidated.
M. Rizzato, Stefano Brignola, G. Munari, M. Gatti, V. Dadduzio, C. Borga, F. Bergamo, A. Pellino, Valentina Angerilli, C. Mescoli, M. Guido, J. Rearden, E. Gringeri, U. Cillo, A. D. Dei Tos, V. Zagonel, F. Loupakis, S. Lonardi, M. Fassan   +18 more
semanticscholar   +1 more source

Inhibition of FGFR2 enhances chemosensitivity to gemcitabine in cholangiocarcinoma through the AKT/mTOR and EMT signaling pathways.

Life Science, 2022
AIM To investigate the oncogenic role of FGFR2 in carcinogenesis in cholangiocarcinoma (CCA) cells. In addition, the feasibility of using FGFR inhibitors in combination with standard chemotherapy was also explored for the chemosensitizing effect in CCA ...
Rattanaporn Jaidee, V. Kukongviriyapan, L. Senggunprai, A. Prawan, Apinya Jusakul, Phatthamon Laphanuwat, S. Kongpetch   +6 more
semanticscholar   +1 more source

FGFR2-IIIb Expression by Immunohistochemistry Has High Specificity in Cholangiocarcinoma with FGFR2 Genomic Alterations

Digestive Diseases and Sciences, 2021
FGFR2 genomic alterations are observed in 10-20% of cholangiocarcinoma (CCA). Although FGFR2 fusions are an important actionable target, FGFR2 protein expression has not been thoroughly characterized.To evaluate FGFR2 protein expression in cholangiocarcinoma harboring FGFR2 genomic alterations.FGFR2 protein expression was evaluated in 99 CCA cases with
Pedro Luiz Serrano Uson Junior, Thomas T. DeLeon, James M. Bogenberger, Rish K. Pai, Heidi E. Kosiorek, Jun Yin, Daniel H. Ahn, Mohammad Bassam Sonbol, Tanios Bekaii-Saab, Aaron S. Mansfield, Kenneth Buetow, Gregory J. Gores, Rory Smoot, George Vasmatzis, Benjamin R. Kipp, Amit Mahipal, Alexander T. Baker, Hani Babiker, Oumar Barro, Chelsae Dumbauld, Yumei Zhou, Faaiq N. Aslam, Michael Barrett, Bertram Jacobs, Nathalie Meurice, Mansi Arora, Joachim Petit, Natalie Elliott, Bolni Nagalo, Marcela A. Salomao, Mitesh J. Borad   +30 more
openaire   +2 more sources

A novel mutation in FGFR2

American Journal of Medical Genetics Part A, 2014
Craniosynostosis is a congenital anomaly that can occur as an isolated condition or as part of a syndrome. Although several genes are known to cause syndromic craniosynostosis, only 24% can be attributed to known genes. Therefore, it is likely that more mutations and other genes are involved.
Goos, Jacqueline, van den Ouweland, Ans, Swagemakers, Sigrid, Verkerk, Annemieke, Hoogeboom, Jeannette, van Veelen - Vincent, M.L.C., Mathijssen, Irene, van der Spek, Peter   +7 more
openaire   +3 more sources

FGFR2 inhibition could suppress spermatogenesis.

Journal of Clinical Oncology, 2020
e15659 Background: The incidence of cancer among the people of reproductive age is constantly increasing. Although FGF2/FGFR2 expression in the male reproductive tract has been reported, there is no evidence of the impact of FGFRs inhibitors on sperm function.
Ilya Tsimafeyeu, Nataliya Lapina, Mikhail Byakhov, Nadezhda Dragun, Evgenia Gavrilova, Anastasia Skorobogatova, Kira Stosman, Marina Melikhova, Olga Vakunenkova, Vadim Kashuro, Mikhail Rozhko, Sergei Tjulandin   +11 more
openaire   +1 more source

Infigratinib in patients with advanced cholangiocarcinoma with FGFR2 gene fusions/translocations: the PROOF 301 trial.

Future Oncology, 2020
Cholangiocarcinoma is an aggressive malignancy with poor overall survival. Approximately 15% of intrahepatic cholangiocarcinomas contain FGFR alterations. Infigratinib is an oral FGFR 1-3 kinase inhibitor.
S. Makawita, Ghassan K Abou-Alfa, S. Roychowdhury, S. Sadeghi, I. Borbath, L. Goyal, A. Cohn, A. Lamarca, D. Oh, T. Macarulla, Rachna T Shroff, M. Howland, Ai Li, T. Cho, A. Pande, M. Javle   +15 more
semanticscholar   +1 more source